Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Detalles Bibliográficos
Autores principales: Yuan, Min, Zhu, Zhongzheng, Mao, Wei, Wang, Hui, Qian, Hong, Wu, Jianguo, Guo, Xianling, Xu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764437/
https://www.ncbi.nlm.nih.gov/pubmed/35059318
http://dx.doi.org/10.3389/fonc.2021.796625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764437/
https://www.ncbi.nlm.nih.gov/pubmed/35059318
http://dx.doi.org/10.3389/fonc.2021.796625

Ejemplares similares